Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Date:3/31/2008

ID-TLR) rates were comparable, at 3.8 percent for the XIENCE V (PROMUS) Stent and 6.8 percent for the TAXUS Stent (p=0.33). Major adverse cardiac events (MACE) rates comprised of cardiac death, all MI and ID-TLR were also comparable, at 6.6 percent for the XIENCE V (PROMUS) Stent and 11.0 percent for the TAXUS Stent (p=0.31).

Stent thrombosis rates at two years using the Academic Research Consortium (ARC) definite/probable definition were low for both the XIENCE V (PROMUS) Stent (0.9%) and the TAXUS Stent (1.4%). Angiographic outcomes showed numerically equivalent late loss, with 0.33 mm for XIENCE V (PROMUS) and 0.34 mm for TAXUS (p=0.60). In-stent binary restenosis rates at two years were also comparable for the XIENCE V (PROMUS) Stent and the TAXUS Stent (2.1% vs. 2.9%, p=1.0).

"Boston Scientific's two DES platforms - the TAXUS and PROMUS Stents - both performed extremely well in the SPIRIT II Trial out to two years," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The data, once again, demonstrated impressive safety and efficacy profiles with low stent thrombosis rates and similar clinical outcomes. We look forward to future data from the SPIRIT Clinical Trial Program as well as from our PROENCY Registries in Europe and the United States - the first to observe different 'Olimus-eluting coronary stents in a real-world setting."

In February, Boston Scientific announced that the first patient had been enrolled in its PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European Registry. The registry will collect real-life clinical outcome data for the PROMUS Stent and compare them with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients in routine clinical practice. A U.S. PROENCY Registry is expected to begin enrolling patients in July and complete enrollment by the end of 2008.

The XIENCE(TM) V (PROMUS) Stent is currently pending approval by
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ... markets. The European radioembolization sphere market ...
(Date:1/15/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ... the seller in cash, without interest (less any required ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014 /PRNewswire/ ... addressing the unmet needs of severely obese patients, ... study of beloranib, a selective inhibitor of methionine ... (PWS), a severe form of genetic obesity.  These ... and body composition, including reductions in body fat ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... A Duke University pioneer in personalized medicine at ... National Conference said physicians must lead the way in ... preventive care. , Dr. Ralph Snyderman, director of the ... that personalized medicine based on genetic and other individual ...
... N.J., Oct. 1 Bayer HealthCare Pharmaceuticals, Inc., ... Administration (FDA) approved a new indication for Mirena® ... menstrual bleeding in women who choose to use ... Mirena provides an effective, non-surgical option for the ...
Cached Medicine Technology:Personalized Medicine Expert: Don't 'Fix It,' 'Predict It' 2FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users 2FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users 3FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... the nation,s leader in pain prescription monitoring, announced ... with Aetna to offer Aetna,s network of providers ... monitoring process. Ameritox,s patented Rx Guardian(SM) methodology is ... a patented methodology to help physicians assess whether ...
... The Ohio State University , Cardinal Health and ... a collaboration that will invest more than $10 million ... industry, combining Ohio State,s Wright Center of Innovation in ... commercialization expertise for molecular imaging agents.Molecular imaging is one ...
... LINE OF NATURAL, NON-TOXIC AND EFFECTIVE HOUSEHOLD CLEANERS OFFER ... FAMILIES CLEAN AND SAFENEW YORK, April 29 ... Kevin Schwartz and Keith Garber of KAS Direct, founders ... cleaning solutions for households with infants and growing families ...
... Security Intelligence, and Risk Management Tools Now All in One ... ... swine flu, political instability, kidnapping and piracy dominating global headlines, MEDEX ... intelligence across medical, security, travel and risk management disciplines. By ...
... released today by the Center to Expose and Close Animal ... Close Animal Factories (CECAF) will hold a media teleconference to ... "factories." Among the topics will be Smithfield Foods at ... Officials in Mexico are looking at "manure lagoons" and ...
... Action to Protect Public,s Oral HealthCHICAGO, April 29 ... exclusively for the general dentist, reminds legislators that dentistry is ... must be taken into consideration in any effort by Congress ... critical issue for general dentistry is access to care. The ...
Cached Medicine News:Health News:Ameritox(R) Contracts With Aetna for Prescription Drug Monitoring Services 2Health News:The Ohio State University, Cardinal Health, State of Ohio to Invest $10 Million to Advance Medical Imaging Industry 2Health News:Preventative Safety Tips Timed to Swine Flu Outbreak 2Health News:MEDEX Announces New, Enhanced and Customizable Member Center 2Health News:MEDEX Announces New, Enhanced and Customizable Member Center 3Health News:MEDEX Announces New, Enhanced and Customizable Member Center 4Health News:Academy of General Dentistry Access to Care White Paper 2
Bausch & Lomb round and rectangular magnifiers incorporate precision optics and an ergonomic design for increased clarity and comfort during use...
Adjustable piston accommodates 7 - 9 mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9 mm trephine blades and 18 mm diameter Teflon block. Designed for accurate ...
... allows the surgeon to effectively ... scrub-resistant, gentian violet ink. All ... sterile, with a ruler and ... pouches. Micro tip marker for ...
Broad tip, gentian violet, sterile, disposable...
Medicine Products: